The instant invention provides for compounds which comprise substituted
triazoloquinazolinones that inhibit CHK1 activity. The invention also
provides for compositions comprising such inhibitory compounds and
methods of inhibiting CHK1 activity by administering the compound to a
patient in need of treatment of cancer.